查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物製藥第三方物流市場-全球市場規模、佔有率、趨勢分析、機遇和預測報告，2019-2029
市場調查報告書
商品編碼
1319294

生物製藥第三方物流市場-全球市場規模、佔有率、趨勢分析、機遇和預測報告，2019-2029

Biopharmaceutical Third-party Logistics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Supply Chain ; By Services ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2029年全球生物製藥第三方物流（3PL）市場規模將達到1496.2億美元

由於對專業處理和存儲的需求不斷成長以及生物製藥供應鏈的日益複雜性，全球生物製藥第三方物流 (3PL) 市場正在蓬勃發展。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 最近估計，2022 年全球生物製藥第三方物流 (3PL) 市場價值將達到 1005 億美元。 BlueWeave預測，2023年至2029年的預測期內，全球生物製藥第三方物流（3PL）市場規模將以5.9%的複合年複合成長率顯著成長，到2029年達到1496.2億美元。我來了。全球生物製藥第三方物流 (3PL) 市場的主要成長促進因素包括物流外包的日益普及、由於銷售量可觀而加強製藥行業分銷網路的努力以及生物學名藥產品的增加。生物製藥行業在開發救生藥物以對抗癌症、糖尿病、呼吸系統疾病和心血管疾病等慢性疾病方面取得了重大進展。因此，隨著生物製藥意識的增強，消費者的需求也在增加。此外，在運輸過程中採用帶有溫度控制系統的先進車輛，再加上盡量減少潛在損壞和人為錯誤的努力，已成為推動生物製藥 3PL 市場成長的關鍵因素。這些進步使生物藥品運輸變得更安全、更可靠。然而，嚴格的品質控制和風險管理預計將在分析期間抑制整體市場的成長。

該報告的詳細分析提供了有關全球生物製藥第三方物流（3PL）市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於為決策者提供全球生物製藥第三方物流（3PL）市場的最新技術趨勢以及行業見解，以做出明智的戰略決策。它還分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球生物製藥第三方物流市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長促進因素
      • 複雜的生物製藥供應鏈
      • 對專業處理和存儲的需求不斷成長
    • 抑制因素
      • 嚴格的品質控制和風險管理
    • 機會
      • 科技的發展
    • 任務
      • 複雜的供應鏈要求
  • 技術進步/最新發展
  • 監管框架
  • 波特五力分析

第4章 全球生物醫藥第三方物流市場概況

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
      • 新鮮食品的）低溫運輸系統
      • 非冷鏈
    • 按服務
      • 交通設施
      • 空運貨物
      • 海運
      • 陸路
      • 倉庫和儲存
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美生物醫藥第三方物流市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
    • 按服務
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲生物製藥第三方物流市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
    • 按服務
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太生物醫藥第三方物流市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
    • 按服務
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和紐西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他地區

第8章 拉丁美洲生物醫藥第三方物流市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
    • 按服務
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 拉丁美洲其他地區

第9章 中東及非洲生物醫藥第三方物流市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按供應鏈
    • 按服務
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭格局

  • 主要公司及其產品列表
  • 2022年全球生物醫藥第三方物流企業市場佔有率分析
  • 通過運行參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作夥伴關係等）

第11章COVID-19對全球生物製藥第三方物流市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人才、主要競爭、聯繫地址、戰略展望、SWOT分析）

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corp.
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Ltd.
  • Agility
  • McKesson Corporation
  • FedEx
  • Other Prominent Players

第13章關鍵戰略建議

第14章調查方法

  • 定性研究
    • 初級和次級研究
  • 定量研究
  • 市場細分和數據三角測量
    • 二次調查
    • 初步調查
  • 主要調查受訪者的地區分佈
  • 假設和限制
簡介目錄
Product Code: BWC23598

Global Biopharmaceutical Third-party Logistics (3PL) Market Size Set to Touch USD 149.62 Billion by 2029.

Global biopharmaceutical Third-party Logistics (3PL) market is flourishing because of an increasing need for specialized handling and storage and growing complexity of the biopharmaceutical supply chain.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global biopharmaceutical third-party logistics (3PL) market size at USD 100.5 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global biopharmaceutical third-party logistics (3PL) market size to grow at a significant CAGR of 5.9% reaching a value of USD 149.62 billion by 2029. Major growth drivers for the global biopharmaceutical third-party logistics (3PL) market include an increasing prevalence of logistics outsourcing, the pharmaceutical industry's commitment to enhancing their distribution networks due to impressive sales figures, and a rise in the introduction of biosimilar products. The biopharmaceutical sector has made remarkable strides in developing life-saving drugs to combat chronic illnesses such as cancer, diabetes, respiratory diseases, and cardiovascular diseases. As a result, consumer demand has escalated in tandem with the growing awareness about biopharmaceuticals. Also, the adoption of advanced vehicles equipped with temperature control systems during transportation, coupled with efforts to minimize potential damage and human errors, has emerged as critical factors propelling the growth of the biopharmaceutical 3PL market. These advancements have elevated the safety and dependability of transporting biopharmaceutical products. However, stringent quality control and risk management is anticipated to restrain the overall market growth during the period in analysis.

Global Biopharmaceutical Third-party Logistics (3PL) Market - Overview:

The global biopharmaceutical third-party logistics (3PL) market encompasses the outsourcing of logistics and supply chain management services by biopharmaceutical companies to specialized providers. These services involve the transportation, warehousing, inventory management, and distribution of biopharmaceutical products, ensuring their safe and timely delivery to different locations worldwide. The increasing number of elderly individuals, escalating occurrence of chronic illnesses, rising healthcare spending, and the surging demand for biopharmaceutical drugs are among the primary drivers necessitating the secure and punctual transportation of medications to various locations. This exponential demand for third-party logistics (3PL) services is rapidly gaining momentum. In addition to biopharmaceuticals, the global patient population is increasingly embracing biosimilar medications, leading to a substantial surge in demand. The remarkable growth of biosimilar medicines is expected to make a substantial contribution to the expansion of the market during the forecast period.

Impact of COVID-19 on Global Biopharmaceutical Third-party Logistics (3PL) Market:

COVID-19 pandemic adversely affected global biopharmaceutical third-party logistics (3PL) market. While the pandemic led to disruptions in global supply chains, the biopharmaceutical industry faced unique challenges in terms of increased demand for essential medical supplies and vaccines. The need for temperature-controlled storage, secure transportation, and timely delivery became even more critical. Logistics providers had to adapt quickly to ensure uninterrupted supply chain operations while adhering to stringent health and safety measures. Additionally, the pandemic accelerated the adoption of digital solutions and advanced technologies to enable remote monitoring, real-time tracking, and efficient inventory management. Despite the challenges, the pandemic highlighted the importance of robust logistics networks, resulting in an increased focus on enhancing the resilience and agility of the biopharmaceutical third-party logistics (3PL) market.

Global Biopharmaceutical Third-party Logistics (3PL) Market - By Services:

Based on services, the global biopharmaceutical third-party logistics (3PL) market is split into Transportation and Warehousing & Storage segments. The warehousing & storage segment holds a higher share in the global biopharmaceutical third-party logistics (3PL) market, due to the significant surge in demand for warehousing and storage services within the life sciences and pharmaceutical sectors. These services play a crucial role in reducing overhead costs for life science companies and contribute to improving their profitability. Service providers in this segment are also offering value-added services, such as warehousing and packaging, which further attract pharmaceutical companies. Also, the incorporation of robots and code scanners has effectively reduced turnaround times, thus driving the growth of the warehousing and storage segment.

Competitive Landscape:

Major players operating in the global biopharmaceutical third-party logistics (3PL) market include: DHL International GmbH, SF Express, United Parcel Service of America, Inc., AmerisourceBergen Corp., DB Schenker, Kuehne and Nagel, Kerry Logistics Network Ltd., Agility, McKesson Corporation, and FedEx. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Biopharmaceutical Third-party Logistics (3PL) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biopharmaceutical Third-party Logistics (3PL) Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Biopharmaceutical Third-party Logistics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Complexity of the Biopharmaceutical Supply Chain
      • 3.2.1.2. Rising Need for Specialized Handling and Storage
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent Quality Control and Risk Management
    • 3.2.3. Opportunities
      • 3.2.3.1. Advancement in Technology
    • 3.2.4. Challenges
      • 3.2.4.1. Complex Supply Chain Requirements
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Biopharmaceutical Third-party Logistics Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Supply Chain
      • 4.2.1.1. Cold Chain
      • 4.2.1.2. Non-cold Chain
    • 4.2.2. By Services
      • 4.2.2.1. Transportation
      • 4.2.2.1.1. Air Freight
      • 4.2.2.1.2. Sea Freight
      • 4.2.2.1.3. Overland
      • 4.2.2.2. Warehousing & Storage
      • 4.2.2.3. Others
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia Pacific (APAC)
      • 4.2.3.4. Latin America (LATAM)
      • 4.2.3.5. Middle East and Africa (MEA)

5. North America Biopharmaceutical Third-party Logistics Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Supply Chain
    • 5.2.2. By Services
    • 5.2.3. By Country
      • 5.2.3.1. United States
      • 5.2.3.1.1. By Supply Chain
      • 5.2.3.1.2. By Services
      • 5.2.3.2. Canada
      • 5.2.3.2.1. By Supply Chain
      • 5.2.3.2.2. By Services

6. Europe Biopharmaceutical Third-party Logistics Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Supply Chain
    • 6.2.2. By Services
    • 6.2.3. By Country
      • 6.2.3.1. Germany
      • 6.2.3.1.1. By Supply Chain
      • 6.2.3.1.2. By Services
      • 6.2.3.2. United Kingdom
      • 6.2.3.2.1. By Supply Chain
      • 6.2.3.2.2. By Services
      • 6.2.3.3. Italy
      • 6.2.3.3.1. By Supply Chain
      • 6.2.3.3.2. By Services
      • 6.2.3.4. France
      • 6.2.3.4.1. By Supply Chain
      • 6.2.3.4.2. By Services
      • 6.2.3.5. Spain
      • 6.2.3.5.1. By Supply Chain
      • 6.2.3.5.2. By Services
      • 6.2.3.6. Belgium
      • 6.2.3.6.1. By Supply Chain
      • 6.2.3.6.2. By Services
      • 6.2.3.7. Russia
      • 6.2.3.7.1. By Supply Chain
      • 6.2.3.7.2. By Services
      • 6.2.3.7.3.
      • 6.2.3.8. The Netherlands
      • 6.2.3.8.1. By Supply Chain
      • 6.2.3.8.2. By Services
      • 6.2.3.9. Rest of Europe
      • 6.2.3.9.1. By Supply Chain
      • 6.2.3.9.2. By Services

7. Asia-Pacific Biopharmaceutical Third-party Logistics Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Supply Chain
    • 7.2.2. By Services
    • 7.2.3. By Country
      • 7.2.3.1. China
      • 7.2.3.1.1. By Supply Chain
      • 7.2.3.1.2. By Services
      • 7.2.3.2. India
      • 7.2.3.2.1. By Supply Chain
      • 7.2.3.2.2. By Services
      • 7.2.3.3. Japan
      • 7.2.3.3.1. By Supply Chain
      • 7.2.3.3.2. By Services
      • 7.2.3.4. South Korea
      • 7.2.3.4.1. By Supply Chain
      • 7.2.3.4.2. By Services
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.5.1. By Supply Chain
      • 7.2.3.5.2. By Services
      • 7.2.3.6. Indonesia
      • 7.2.3.6.1. By Supply Chain
      • 7.2.3.6.2. By Services
      • 7.2.3.7. Malaysia
      • 7.2.3.7.1. By Supply Chain
      • 7.2.3.7.2. By Services
      • 7.2.3.8. Singapore
      • 7.2.3.8.1. By Supply Chain
      • 7.2.3.8.2. By Services
      • 7.2.3.9. Vietnam
      • 7.2.3.9.1. By Supply Chain
      • 7.2.3.9.2. By Services
      • 7.2.3.10. Rest of APAC
      • 7.2.3.10.1. By Supply Chain
      • 7.2.3.10.2. By Services

8. Latin America Biopharmaceutical Third-party Logistics Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Supply Chain
    • 8.2.2. By Services
    • 8.2.3. By Country
      • 8.2.3.1. Brazil
      • 8.2.3.1.1. By Supply Chain
      • 8.2.3.1.2. By Services
      • 8.2.3.2. Mexico
      • 8.2.3.2.1. By Supply Chain
      • 8.2.3.2.2. By Services
      • 8.2.3.3. Argentina
      • 8.2.3.3.1. By Supply Chain
      • 8.2.3.3.2. By Services
      • 8.2.3.4. Peru
      • 8.2.3.4.1. By Supply Chain
      • 8.2.3.4.2. By Services
      • 8.2.3.5. Rest of LATAM
      • 8.2.3.5.1. By Supply Chain
      • 8.2.3.5.2. By Services

9. Middle East & Africa Biopharmaceutical Third-party Logistics Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Supply Chain
    • 9.2.2. By Services
    • 9.2.3. By Country
      • 9.2.3.1. Saudi Arabia
      • 9.2.3.1.1. By Supply Chain
      • 9.2.3.1.2. By Services
      • 9.2.3.2. UAE
      • 9.2.3.2.1. By Supply Chain
      • 9.2.3.2.2. By Services
      • 9.2.3.3. Qatar
      • 9.2.3.3.1. By Supply Chain
      • 9.2.3.3.2. By Services
      • 9.2.3.4. Kuwait
      • 9.2.3.4.1. By Supply Chain
      • 9.2.3.4.2. By Services
      • 9.2.3.5. South Africa
      • 9.2.3.5.1. By Supply Chain
      • 9.2.3.5.2. By Services
      • 9.2.3.6. Nigeria
      • 9.2.3.6.1. By Supply Chain
      • 9.2.3.6.2. By Services
      • 9.2.3.7. Algeria
      • 9.2.3.7.1. By Supply Chain
      • 9.2.3.7.2. By Services
      • 9.2.3.8. Rest of MEA
      • 9.2.3.8.1. By Supply Chain
      • 9.2.3.8.2. By Services

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Biopharmaceutical Third-party Logistics Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Biopharmaceutical Third-party Logistics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. DHL International GmbH
  • 12.2. SF Express
  • 12.3. United Parcel Service of America, Inc.
  • 12.4. AmerisourceBergen Corp.
  • 12.5. DB Schenker
  • 12.6. Kuehne and Nagel
  • 12.7. Kerry Logistics Network Ltd.
  • 12.8. Agility
  • 12.9. McKesson Corporation
  • 12.10. FedEx
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations